Drotaverine, 20 mg/ml 2 ml 10 pcs

Myotropic antispasmodic. Reduces influx of calcium ions into smooth muscle cells (inhibits phosphodiesterase leads to accumulation of intracellular CAMF). Reduces smooth muscle tone of internal organs and intestinal peristalsis dilates blood vessels. It does not affect the autonomic nervous system; it does not penetrate into the central nervous system.

The direct effect on the smooth muscles allows it to be used as an antispasmodic when drugs from the group of M-cholinoblockers are contraindicated (closed-angle glaucoma, prostatic hyperplasia).

In parenteral administration the action of the drug is seen after 2-4 minutes. The maximum effect occurs after 30 minutes.

Pharmacokinetics:

Uniformly distributed in tissues penetrates into smooth muscle cells. Blood plasma protein binding is 95-98%. The half-life period is 2-4 hours. It is mainly excreted by kidneys and to a lesser extent with bile. Does not penetrate through the blood-brain barrier.

Indications

Active ingredient

Composition

One ampoule (2 ml of solution) contains 40 mg of drotaverine hydrochloride as an active ingredient.

Auxiliary substances: sodium metabisulfite (sodium disulfite), ethyl alcohol (ethanol), water for injection.

How to take, the dosage

Intramuscularly or subcutaneously 2-4 ml (40-80 mg) 1-3 times a day. Duration of treatment is 1-2 weeks. If prolonged treatment is necessary, the drug should be taken orally.

In cases when rapid effect is required 2-4 ml (40-80 mg) of the drug are slowly administered intravenously in 10-20 ml of 09% sodium chloride solution or 5% dextrose solution.

In children under 6 years of age the drug is usually prescribed in a dose of 10-20 mg 1-2 times a day for children over 6 years of age in a dose of 20 mg 1-2 times a day.

Interaction

In concomitant use may attenuate the antiparkinsonian effect of levodopa.

Enhances the effects of papaverine bendazole and other antispasmodics (including M cholinoblockers) decrease the blood pressure caused by tricyclic antidepressants quinidine and procainamide.

Limits the antispasmodic activity of morphine.

Phenobarbital increases the spasmolytic effect of drotaverine hydrochloride.

Special Instructions

Contraindications

Individual intolerance; expressed hepatic renal heart failure; II-III degree atrioventricular block; cardiogenic shock; arterial hypotension.

Side effects

Dizziness palpitation decreased blood pressure feeling of fever sweating allergic skin reactions.

In intravenous administration – collapse atrioventricular block arrhythmia suppression of the respiratory center. Nausea and vomiting may occur during rapid intravenous administration.

Overdose

Similarities